Ali Raza Khaki

4.1k total citations
77 papers, 451 citations indexed

About

Ali Raza Khaki is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ali Raza Khaki has authored 77 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 36 papers in Surgery and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ali Raza Khaki's work include Bladder and Urothelial Cancer Treatments (35 papers), Urinary and Genital Oncology Studies (23 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Ali Raza Khaki is often cited by papers focused on Bladder and Urothelial Cancer Treatments (35 papers), Urinary and Genital Oncology Studies (23 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Ali Raza Khaki collaborates with scholars based in United States, United Kingdom and Spain. Ali Raza Khaki's co-authors include Petros Grivas, Leonidas Nikolaos Diamantopoulos, Jeremy L. Warner, Aakash Desai, Mark P. Lythgoe, Maria Pia Morelli, Despina Michailidou, Jonathan Krell, Namrata Singh and Bishal Gyawali and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Molecular Biology and Cancer Research.

In The Last Decade

Ali Raza Khaki

66 papers receiving 447 citations

Peers

Countries citing papers authored by Ali Raza Khaki

Since Specialization

Citations

This map shows the geographic impact of Ali Raza Khaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Raza Khaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Raza Khaki more than expected).

Fields of papers citing papers by Ali Raza Khaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Raza Khaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Raza Khaki. The network helps show where Ali Raza Khaki may publish in the future.

Co-authorship network of co-authors of Ali Raza Khaki

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Raza Khaki. A scholar is included among the top collaborators of Ali Raza Khaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Raza Khaki. Ali Raza Khaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC). 2025 ·Journal of Clinical Oncology ·(unknown), Ali Raza Khaki, (unknown), Petros Grivas, (unknown), Matthew D. Galsky, Shilpa Gupta, Vadim S. Koshkin, Elizabeth R. Plimack, Jacob Rosenberg, Peter H. O’Donnell	0
2	Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial. 2025 ·Journal of Clinical Oncology ·(unknown), Ali Raza Khaki, Mary W. Redman, Kelsey K. Baker, (unknown), (unknown), (unknown), (unknown), Funda Vakar‐Lopez, Todd Yezefski, Michael T. Schweizer, Bruce Montgomery, Evan Y. Yu, Atreya Dash, Sarah P. Psutka, Dingbo Lin, George R. Schade, John L. Gore, Jonathan L. Wright, Petros Grivas	0
3	Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort. 2024 ·Journal of Clinical Oncology ·Drew Rasco, Albiruni Ryan Abdul Razak, Ali Raza Khaki, Alexander I. Spira, (unknown), Anh N. Diep, Maike Schmidt, (unknown), (unknown), Dylan M. Glatt	1
4	An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study 2024 ·Journal of Medical Economics ·Joseph Tkacz, (unknown), Barnabie Agatep, Lorie Ellis, (unknown), Ali Raza Khaki	0
5	Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of ¹⁷⁷Lu-PSMA-617 treatment. 2024 ·Journal of Clinical Oncology ·Hong Song, (unknown), Valentina Ferri, Heying Duan, (unknown), Farshad Moradi, Carina Marí Aparici, Benjamin L. Franc, Guido Davidzon, Colin P. Bergstrom, Alice C. Fan, Sumit Shah, Ali Raza Khaki, Sandy Srinivas, Andrei Iagaru	1
6	Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC). 2024 ·Journal of Clinical Oncology ·(unknown), Gavin Hui, Yen Low, Saurabh Gombar, Alice C. Fan, (unknown), Sumit Shah, Sandy Srinivas, Ali Raza Khaki	1
7	1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE 2024 ·Annals of Oncology ·Amanda Nizam, Li Zhang, (unknown), (unknown), Dimitra Rafailia Bakaloudi, Mehmet Asım Bilen, (unknown), Yousef Zakharia, Matthew I. Milowsky, Deepak Kilari, Christopher Hoimes, Ali Raza Khaki, Hamid Emamekhoo, Saurabh Gupta, (unknown), (unknown), (unknown), Matthew T. Campbell, Omar Alhalabi, (unknown)	0
8	Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer 2024 ·European Journal of Nuclear Medicine and Molecular Imaging ·Hong Song, (unknown), Valentina Ferri, Heying Duan, Carina Marí Aparici, Guido Davidzon, Benjamin L. Franc, Farshad Moradi, (unknown), Colin P. Bergstrom, Alice C. Fan, Sumit Shah, Ali Raza Khaki, Sandy Srinivas, Andrei Iagaru	10
9	The Evolving Therapeutic Landscape and Role of Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Systematic Review 2023 ·(unknown), Dimitrios Makrakis, Petros Grivas, Ali Raza Khaki	1
10	Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC). 2023 ·Journal of Clinical Oncology ·(unknown), Dimitra Rafailia Bakaloudi, (unknown), (unknown), (unknown), Dimitrios Makrakis, Nishita Tripathi, Neeraj Agarwal, (unknown), Vadim S. Koshkin, Jason R. Brown, Jeffrey S. Johnson, Yousef Zakharia, Joseph J. Park, Ajjai Alva, Rafael Morales‐Barrera, Alexandra Drakaki, Pedro C. Barata, Ali Raza Khaki, Petros Grivas	0
11	Patient-reported distress at a cancer center during the COVID-19 pandemic 2023 ·Scientific Reports ·(unknown), (unknown), (unknown), Ali Raza Khaki, Tina Hernandez‐Boussard, Kavitha Ramchandran	1
12	Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020 2022 ·Cancer Investigation ·(unknown), Aakash Desai, Michael Glover, Gavin Hui, Kavitha Ramchandran, Heather A. Wakelee, Mark P. Lythgoe, Ali Raza Khaki	1
13	Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors 2021 ·Scientific Reports ·Despina Michailidou, Ali Raza Khaki, Maria Pia Morelli, Leonidas Nikolaos Diamantopoulos, Namrata Singh, Petros Grivas	61
14	157P Racial diversity and reporting in FDA registration trials for breast cancer from 2006 to 2021 2021 ·Annals of Oncology ·Mark P. Lythgoe, Jonathan Krell, Laura Kenny, Ali Raza Khaki	1
15	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists 2020 ·Cancer Investigation ·Laura Graham, Alexandra Sokolova, Ali Raza Khaki, Qian Wu, Nancy E. Davidson	2
16	771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer 2020 ·Annals of Oncology ·Vadim S. Koshkin, Yi Sun, (unknown), (unknown), Christopher Su, (unknown), Ali Raza Khaki, Andrew R. Johnson, (unknown), (unknown), Arnab Basu, (unknown), Nancy B. Davis, Petros Grivas, Matthew I. Milowsky, Deepak Kilari, Ajjai Alva	2
17	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19) 2020 ·Annals of Oncology ·Petros Grivas, Jeremy L. Warner, Yu Shyr, Dimpy P. Shah, (unknown), (unknown), Toni K. Choueiri, Donna R. Rivera, Corrie Painter, Michael A. Thompson, Solange Peters, Aakash Desai, Ali Raza Khaki, Nathan A. Pennell, Jessica E. Hawley, Balázs Halmos, Matthew Puc, Gary H. Lyman, Brian I. Rini, G. Lopes	10
18	Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data 2019 ·Journal of the National Comprehensive Cancer Network ·Ali Raza Khaki, (unknown), Vinay Prasad	1
19	Study on the effect of Thymus vulgaris essential oil on humoral immunity and performance of broiler chickens after La Sota vaccination. 2013 ·Annals of biological research ·(unknown), (unknown), Ali Raza Khaki, (unknown), (unknown), (unknown), (unknown), (unknown)	13
20	The Macroscopic Rate of Nucleic Acid Translocation by Hepatitis C Virus Helicase NS3h Is Dependent on Both Sugar and Base Moieties 2010 ·Journal of Molecular Biology ·Ali Raza Khaki, (unknown), Shuja Shafi Malik, Anita Niedziela‐Majka, Stephanie A. Leavitt, Ruth Wang, Magdeleine Hung, Roman Sakowicz, Katherine M. Brendza, Christopher J. Fischer	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact